Recovery research fieldbook Evidence, not treatment advice
Recovery archive

Published recovery field note

BPC-157 vs TB-500 — Peptide Comparison

BPC-157 vs TB-500 — compare dosing, benefits, safety profiles, side effects, and how they stack. See which peptide is right for you.

Context first

Study findings do not automatically establish clinical benefit, safety, dosing, or suitability for an individual.

At a Glance

Quickcomparison

Dose Range

BPC-157

250–500 mcg

TB-500

2–5 mg

Frequency

Once daily

Twice weekly

Administration

Subcutaneous injection

Cycle Length

4-6 weeks

Onset Speed

Moderate (1-2 weeks)

Evidence Level

Strong preclinical (extensive animal studies)

Moderate human trials (Phase 1-2)

Efficacy

Benefitratings

Primary Benefit

Secondary Benefit

Additional Benefit

Healing Speed

Tissue Repair

Anti-Scarring

Technical Data

Compoundspecifications

Molecular Formula

C62H98N16O22

Molecular Weight

1419.53 g/mol

Half-Life

4-6 hours

Bioavailability

~100% (subcutaneous)

CAS Number

137525-51-0

C38H68N10O14

889.01 g/mol

2-3 days (systemic)

High via subcutaneous injection (~100%)

885340-08-9

Protocols

Dosingtiers

starting

250 mcg

1-2 weeks

A common starting amount in research practice, often injected near the injured area. BPC-157 has no human dose-finding trials, so doses come from animal studies and documented practice [1][2].

standard

250-500 mcg

Twice daily

Commonly used range for tissue and tendon recovery in research practice [1][3].

advanced

500 mcg

6-8 weeks

Upper end used in practice for more demanding acute injuries [1][3].

2-2.5 mg

Loading phase, 4-6 weeks

Research peptide with no human trials of the fragment; loading doses used in practice [6].

Once weekly

Maintenance after loading

Maintenance dose used in practice following the loading phase [6].

Applications

Bestsuited for

Tendon and ligament injuries

Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair

Gut healing

IBS, leaky gut, ulcers, inflammatory bowel conditions - derived from gastric juice, it has a natural affinity for digestive tissue

Muscle injuries

Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression

Joint problems

Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties

Post-surgical recovery

Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms

Athletes Recovering from Muscle Injuries

If you've pulled a hamstring, strained your back, or torn a muscle, TB-500 helps accelerate the healing process by promoting cell migration to the injury site and supporting new blood vessel growth. It's especially useful for injuries that just won't seem to fully heal.

Tendon and Ligament Problems

Tendons and ligaments are notoriously slow healers because they have poor blood supply. TB-500 promotes angiogenesis (new blood vessel formation) and helps repair these stubborn connective tissue injuries—think Achilles tendonitis, tennis elbow, or rotator cuff issues.

Post-Surgical Recovery

After surgery, your body needs to repair a lot of tissue quickly. TB-500 supports wound healing, reduces inflammation, and may help minimize scar tissue formation. Some protocols use it alongside traditional recovery to potentially speed up the healing timeline.

Chronic Inflammation and Slow Healers

Some people just heal slowly—whether due to age, diabetes, or other factors. TB-500 helps regulate the inflammatory response and promotes the cellular processes needed for tissue repair. It essentially tells your body to focus healing resources where they're needed most.

Safety Profile

Sideeffects

Common

Injection site redness

Mild nausea

Dizziness

Uncommon

Headache

Fatigue

Hot/cold sensations

Serious

Allergic reaction

Mild fatigue or lethargy

Mild headache

Slight flushing

Head rush or lightheadedness

Temporary nausea

Research Status

Safety& evidence

FDA Status

Research compound

Safety Overview

BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. No FDA approval exists. Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.

Contraindications

xPregnancy

xBreastfeeding

xActive cancer

xHistory of cancer

TB-500 has shown a good safety profile across preclinical studies and limited human research. It's a fragment of thymosin beta-4, a naturally occurring protein in your body involved in healing. Most side effects are mild and transient, primarily injection site reactions. However, large-scale clinical trials are still needed to fully establish its safety profile in humans.

xPregnancy or planning to become pregnant

xCurrently breastfeeding

xActive cancer or history of cancer

xKnown allergy to peptide components

xChildren and adolescents

Decision Guide

Which isright for you?

Choose BPC-157 if...

Injury recovery

Post-surgery healing

Chronic pain management

Gut health

Choose TB-500 if...

Accelerating injury recovery

Tendon and ligament healing

Reducing chronic inflammation

Post-surgical recovery support

Connected topics

Follow this recovery question